MedTrace Logo

Stereotactic Boost and Short-course Radiation Therapy for Oropharynx Cancer

NCT04178174 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2025-05-18

No results posted yet for this study

Summary

This is a randomized clinical trial comparing the outcomes of short-course chemoradiation consisting in stereotactic boost to the gross tumor and de-esclalated chemoradiation to the elective neck in human papilloma associated oropharynx cancer vs. the current standard 7-week course chemoradiation.

Conditions

Interventions

RADIATION

SABR boost and de-escalated chemoradiation

Stereotactic body radiotherapy boost to the gross tumor volume to a dose of 14 Gy in 2 fractions, followed by cisplatin-based chemoradiation to a dose of 40 Gy in 20 fractions

RADIATION

Standard chemoradiation

Standard Cisplatin-based chemoradiation to a dose of 70 Gy in 33 fractions

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    collaborator OTHER

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    collaborator OTHER

  • Jewish General Hospital

    collaborator OTHER

  • Centre hospitalier de l'Université de Montréal (CHUM)

    lead OTHER

Principal Investigators

  • Houda Bahig, MD PhD · Centre hospitalier de l'Université de Montréal (CHUM)

  • Phuc-Felix Nguyen-Tan, MD · Centre hospitalier de l'Université de Montréal (CHUM)

  • David Palma, MD PhD · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

  • Jack Phan, MD PhD · M.D. Anderson Cancer Center

  • Khalil Sultanem, MD · Montreal Jewish General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-23
Primary Completion
2027-12-31
Completion
2029-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04178174 on ClinicalTrials.gov